Cathelicidin Antimicrobial Peptide — Human Innate Immunity
The only known human cathelicidin — a 37-amino acid peptide produced naturally throughout the body in skin, gut, lungs, and immune cells. LL-37 is the frontline antimicrobial defender of human innate immunity, with broad-spectrum activity against bacteria, viruses, and fungi alongside potent immunomodulatory signalling. Research spans wound healing, leaky gut, respiratory infections, skin conditions, and cancer immunology. Human clinical trials are ongoing in wound healing and dermatology.
01 — Research Summary
LL-37 has one of the largest research datasets of any compound on this site — over 400 published studies — reflecting its central role in innate immunity research. The evidence spans antimicrobial activity, wound healing, immunomodulation, and emerging oncology applications.
Significantly accelerated chronic wound closure. A Phase 2 clinical trial in chronic wound patients demonstrated topical LL-37 significantly accelerated wound closure rates versus standard care — the most advanced human clinical data available and the primary driver of ongoing trials.
Lower LL-37 levels correlate with more severe COVID-19 outcomes. Observational research during the COVID-19 pandemic found patients with lower circulating LL-37 levels experienced more severe disease outcomes — consistent with its role in antiviral innate immunity and generating interest in its potential as a respiratory immune support compound.
LL-37 restored gut barrier integrity in permeability models. Research demonstrated LL-37 directly supports tight junction protein expression in gut epithelium — contributing to barrier integrity restoration. This gut application is mechanistically sound and growing in community interest.
Dysregulation of LL-37 implicated in both conditions. Research clarified that both rosacea (excess LL-37 processing) and certain immune skin conditions involve LL-37 dysregulation — making the peptide both a therapeutic target and a potential treatment depending on the specific application, adding complexity to topical use.
02 — Mechanism of Action
LL-37 is unusually multi-functional — it is simultaneously a direct antimicrobial agent, an immune modulator, a wound healing promoter, and a signalling molecule. This breadth reflects its central role in innate immunity.
LL-37's cationic amphipathic structure allows it to selectively disrupt the membranes of bacteria, fungi, and enveloped viruses — organisms that have negatively charged membranes — while leaving mammalian cells largely intact due to their different membrane composition. This direct killing mechanism is the foundation of its antimicrobial role.
LL-37 modulates toll-like receptor (TLR) signalling — the pattern recognition system of innate immunity. It can both activate TLR responses (amplifying immune detection of pathogens) and suppress excessive TLR activation (preventing damaging inflammatory overreaction) — a context-dependent immunomodulatory role.
LL-37 directly activates fibroblasts and keratinocytes to proliferate and migrate into wound sites — promoting the epithelialisation and granulation tissue formation stages of healing. This effect is independent of its antimicrobial activity and explains its wound healing clinical trial focus.
In the gut, LL-37 supports tight junction protein expression and epithelial cell proliferation — maintaining the physical barrier that prevents pathogen translocation and reduces systemic inflammatory burden. This mechanism is the basis for its application in leaky gut research.
LL-37 disrupts bacterial biofilms — the protective matrices that make chronic infections resistant to antibiotics. This anti-biofilm mechanism makes it particularly relevant to chronic wound infections and resistant respiratory infections where biofilm formation is a key pathological feature.
LL-37 has an interesting relationship with rosacea: rosacea skin shows abnormal processing of the LL-37 precursor, producing peptide fragments that trigger inflammation rather than serving their normal antimicrobial function. This means topical LL-37 in rosacea-prone skin requires careful consideration — it is not straightforwardly beneficial in this condition and may worsen symptoms. For other skin applications (wound healing, normal antimicrobial support), the situation is different. Know your skin condition before applying.
03 — Dosing Protocols
LL-37 is used both topically and by injection depending on the application. Topical is most established for skin and wound applications; injectable for systemic immune support.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Topical — wound / skin | 0.1–1% solution | 1–2x daily | Until resolved | Apply directly to wound or affected skin. Established by Phase 2 trial data. |
| Subcutaneous — systemic | 100–500 mcg | 3x per week | 4–8 week cycles | Community protocol for systemic immune support. Limited human data at this dose. |
| Nasal — respiratory | 50–100 mcg | Daily during illness | Short courses | Nasal administration for respiratory infection support. Emerging use case. |
| Combined with BPC-157 | 200 mcg LL-37 + 250 mcg BPC-157 | Daily | 8 weeks | Gut healing combination — antimicrobial protection plus tissue repair. |
LL-37 is generally well-tolerated but the dose-response relationship matters — excessive concentrations can cause pro-inflammatory effects rather than anti-inflammatory ones. Topical application to rosacea-affected skin should be approached with caution. Injectable use should start at the lower end of the dose range. Not FDA-approved for therapeutic use though human trials are ongoing.
04 — Community Experiences
LL-37 is discussed in immune health, gut healing, and skin communities. Its unique status as the only human cathelicidin gives it a credibility foundation that pure research peptides lack — it is something your body makes, just in declining amounts with age and illness. Community discussions focus heavily on gut applications (alongside BPC-157 and KPV), wound healing, and immune support during illness.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"Running LL-37 + BPC-157 + KPV for gut healing. The combination covers antimicrobial protection (LL-37), tissue repair (BPC-157), and inflammation control (KPV). 8 weeks in and gut permeability markers improved significantly on testing..."
"The Phase 2 data is the most advanced human evidence for any compound in the antimicrobial peptide space. Topical application for wound healing has genuine clinical backing — not just biohacker anecdote..."
"Used nasal LL-37 at the first sign of respiratory infection for three winters. Subjectively shorter duration and reduced severity. Mechanistically plausible — it's a frontline antiviral agent. Hard to prove causality but I'll keep running it..."
"LL-37 is a 37-amino acid peptide — longer than most compounds in the research market. Synthesis difficulty is higher, and the market has more poorly synthesised product than shorter peptides. Mass spec verification is non-negotiable here..."